BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M. Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014;9:126-133. [PMID: 25514916 DOI: 10.2174/1574887109666141216111143] [Cited by in Crossref: 150] [Cited by in F6Publishing: 153] [Article Influence: 25.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee J, Kim Y, Friso S, Choi SW. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2016; Nov 23. [Epub ahead of print]. [PMID: 27889327 DOI: 10.1016/j.mam.2016.11.008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 11.6] [Reference Citation Analysis]
2 Mencin AA, Loomba R, Lavine JE. Caring for children with NAFLD and navigating their care into adulthood. Nat Rev Gastroenterol Hepatol 2015;12:617-28. [PMID: 26323878 DOI: 10.1038/nrgastro.2015.146] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
3 Hashimoto Y, Hamaguchi M, Fukuda T, Ohbora A, Kojima T, Fukui M. Fatty liver as a risk factor for progression from metabolically healthy to metabolically abnormal in non-overweight individuals. Endocrine 2017;57:89-97. [DOI: 10.1007/s12020-017-1313-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
4 Alwahsh SM, Dwyer BJ, Forbes S, Thiel DH, Lewis PJ, Ramadori G. Insulin Production and Resistance in Different Models of Diet-Induced Obesity and Metabolic Syndrome. Int J Mol Sci 2017;18:E285. [PMID: 28134848 DOI: 10.3390/ijms18020285] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
5 Wehmeyer MH, Zyriax BC, Jagemann B, Roth E, Windler E, Schulze Zur Wiesch J, Lohse AW, Kluwe J. Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Medicine (Baltimore) 2016;95:e3887. [PMID: 27281105 DOI: 10.1097/MD.0000000000003887] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
6 Itoh H, Muramatsu-Kato K, Ferdous UJ, Kohmura-Kobayashi Y, Kanayama N. Undernourishment in utero and hepatic steatosis in later life: A potential issue in Japanese people. Congenit Anom (Kyoto) 2017;57:178-83. [PMID: 27859643 DOI: 10.1111/cga.12200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jiang W, Guo MH, Hai X. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat. World J Gastroenterol 2016; 22(46): 10180-10188 [PMID: 28028366 DOI: 10.3748/wjg.v22.i46.10180] [Cited by in CrossRef: 59] [Cited by in F6Publishing: 47] [Article Influence: 11.8] [Reference Citation Analysis]
8 Lorbeer R, Bayerl C, Auweter S, Rospleszcz S, Lieb W, Meisinger C, Heier M, Peters A, Bamberg F, Hetterich H. Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease. J Hypertens 2017;35:737-44. [PMID: 28253218 DOI: 10.1097/HJH.0000000000001245] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Wei YT, Lee PY, Lin CY, Chen HJ, Lin CC, Wu JS, Chang YF, Wu CL, Guo HR. Non-alcoholic fatty liver disease among patients with sleep disorders: a Nationwide study of Taiwan. BMC Gastroenterol 2020;20:32. [PMID: 32041532 DOI: 10.1186/s12876-020-1178-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
10 Tsunoda K, Kai Y, Kitano N, Uchida K, Kuchiki T, Nagamatsu T. Impact of physical activity on nonalcoholic steatohepatitis in people with nonalcoholic simple fatty liver: A prospective cohort study. Prev Med 2016;88:237-40. [PMID: 27143495 DOI: 10.1016/j.ypmed.2016.04.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
11 Itoh H, Kanayama N. Developmental Origins of Nonalcoholic Fatty Liver Disease (NAFLD). Adv Exp Med Biol 2018;1012:29-39. [PMID: 29956192 DOI: 10.1007/978-981-10-5526-3_4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
12 Oliveira CP, de Lima Sanches P, de Abreu-Silva EO, Marcadenti A. Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease. J Diabetes Res. 2016;2016:4597246. [PMID: 26770987 DOI: 10.1155/2016/4597246] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
13 Kwak JH, Jun DW, Lee SM, Cho YK, Lee KN, Lee HL, Lee OY, Choi HS, Yoon BC. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: A cross-sectional study. Clin Nutr. 2018;37:1550-1557. [PMID: 28918170 DOI: 10.1016/j.clnu.2017.08.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
14 Katchman H, Zelber-sagi S, Baruch R, Berman G, Schwartz IF, Schwartz D, Nakache R, Goykhman Y, Katz P, Shibolet O, Shashar M, Grupper A. Progression and new onset of nonalcoholic fatty liver disease in living kidney donors compared to healthy controls. Clin Transplant 2018;32:e13240. [DOI: 10.1111/ctr.13240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 13.8] [Reference Citation Analysis]
16 López-Lemus UA, Garza-Guajardo R, Barboza-Quintana O, Rodríguez-Hernandez A, García-Rivera A, Madrigal-Pérez VM, Guzmán-Esquivel J, García-Labastida LE, Soriano-Hernández AD, Martínez-Fierro ML, Rodríguez-Sánchez IP, Sánchez-Duarte E, Cabrera-Licona A, Ceja-Espiritu G, Delgado-Enciso I. Association Between Nonalcoholic Fatty Liver Disease and Severe Male Reproductive Organ Impairment (Germinal Epithelial Loss): Study on a Mouse Model and on Human Patients. Am J Mens Health 2018;12:639-48. [PMID: 29577833 DOI: 10.1177/1557988318763631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
17 Betanzos-Robledo L, Cantoral A, Peterson KE, Hu H, Hernández-Ávila M, Perng W, Jansen E, Ettinger AS, Mercado-García A, Solano-González M, Sánchez B, Téllez-Rojo MM. Association between cumulative childhood blood lead exposure and hepatic steatosis in young Mexican adults. Environ Res 2021;196:110980. [PMID: 33691159 DOI: 10.1016/j.envres.2021.110980] [Reference Citation Analysis]
18 Hu J, Xu Y, He Z, Zhang H, Lian X, Zhu T, Liang C, Li J. Increased risk of cerebrovascular accident related to non-alcoholic fatty liver disease: a meta-analysis. Oncotarget. 2017;9:2752-2760. [PMID: 29416808 DOI: 10.18632/oncotarget.22755] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
19 Jamsheena V, Mishra RK, Veena KS, Sini S, Jayamurthy P, Lankalapalli RS. New 1,2-Dihydropyridine-Based Fluorophores and Their Applications as Fluorescent Probes. ACS Omega 2018;3:856-62. [PMID: 30023792 DOI: 10.1021/acsomega.7b01835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
20 Chen G, Ni Y, Nagata N, Xu L, Ota T. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17:1379. [PMID: 27563875 DOI: 10.3390/ijms17091379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
21 Zheng X, Ren W, Gong L, Long J, Luo R, Wang Y. The Great Chinese Famine Exposure in Early Life and the Risk of Nonalcoholic Fatty Liver Disease in Adult Women. Ann Hepatol 2017;16:901-8. [PMID: 29055916 DOI: 10.5604/01.3001.0010.5281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
22 Federico A, Dallio M, Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules 2017;22:E191. [PMID: 28125040 DOI: 10.3390/molecules22020191] [Cited by in Crossref: 132] [Cited by in F6Publishing: 109] [Article Influence: 33.0] [Reference Citation Analysis]
23 Cheng F, Ma C, Wang X, Zhai C, Wang G, Xu X, Mu J, Li C, Wang Z, Zhang X, Yue W, Du X, Lian Y, Zhu W, Yin X, Wei Z, Song W, Wang Q. Effect of traditional Chinese medicine formula Sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: a rat study. BMC Complement Altern Med. 2017;17:203. [PMID: 28388904 DOI: 10.1186/s12906-017-1707-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
24 Beck JR, Lawrence A, Tung AS, Harris EN, Stains CI. Interrogating Endogenous Protein Phosphatase Activity with Rationally Designed Chemosensors. ACS Chem Biol 2016;11:284-90. [DOI: 10.1021/acschembio.5b00506] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
25 Liu CQ, He CM, Chen N, Wang D, Shi X, Liu Y, Zeng X, Yan B, Liu S, Yang S, Li X, Li X, Li Z. Serum uric acid is independently and linearly associated with risk of nonalcoholic fatty liver disease in obese Chinese adults. Sci Rep. 2016;6:38605. [PMID: 27924915 DOI: 10.1038/srep38605] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
26 Marciano F, Savoia M, Vajro P. Celiac disease-related hepatic injury: Insights into associated conditions and underlying pathomechanisms. Dig Liver Dis. 2016;48:112-119. [PMID: 26711682 DOI: 10.1016/j.dld.2015.11.013] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
27 Jeong HS, Cho YH, Kim KH, Kim Y, Kim KS, Na YC, Park J, Lee IS, Lee JH, Jang HJ. Anti-lipoapoptotic effects of Alisma orientalis extract on non-esterified fatty acid-induced HepG2 cells. BMC Complement Altern Med 2016;16:239. [PMID: 27456850 DOI: 10.1186/s12906-016-1181-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
28 Cardoso AC, de Figueiredo-Mendes C, A Villela-Nogueira C. Current management of NAFLD/NASH. Liver Int 2021;41 Suppl 1:89-94. [PMID: 34155799 DOI: 10.1111/liv.14869] [Reference Citation Analysis]
29 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
30 Ichimura-Shimizu M, Tsuchiyama Y, Morimoto Y, Matsumoto M, Kobayashi T, Sumida S, Kakimoto T, Oya T, Ogawa H, Yamashita M, Matsuda S, Omagari K, Taira S, Tsuneyama K. A Novel Mouse Model of Nonalcoholic Steatohepatitis Suggests that Liver Fibrosis Initiates around Lipid-Laden Macrophages. Am J Pathol 2021:S0002-9440(21)00440-5. [PMID: 34710382 DOI: 10.1016/j.ajpath.2021.10.002] [Reference Citation Analysis]
31 Liu Y, Liu C, Shi X, Lin M, Yan B, Zeng X, Chen N, Lu S, Liu S, Yang S. Correlations of non-alcoholic fatty liver disease and serum uric acid with subclinical atherosclerosis in obese Chinese adults. J Diabetes. 2016; Jul 1. [Epub ahead of print]. [PMID: 27371101 DOI: 10.1111/1753-0407.12441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
32 Kobyliak N, Abenavoli L, Falalyeyeva T, Virchenko O, Natalia B, Beregova T, Bodnar P, Spivak M. Prevention of NAFLD development in rats with obesity via the improvement of pro/antioxidant state by cerium dioxide nanoparticles. Clujul Med 2016;89:229-35. [PMID: 27152074 DOI: 10.15386/cjmed-632] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
33 Zhu JZ, Hollis-Hansen K, Wan XY, Fei SJ, Pang XL, Meng FD, Yu CH, Li YM. Clinical guidelines of non-alcoholic fatty liver disease: A systematic review. World J Gastroenterol 2016; 22(36): 8226-8233 [PMID: 27688665 DOI: 10.3748/wjg.v22.i36.8226] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
34 Zhou J, Ho CT, Long P, Meng Q, Zhang L, Wan X. Preventive Efficiency of Green Tea and Its Components on Nonalcoholic Fatty Liver Disease. J Agric Food Chem 2019;67:5306-17. [PMID: 30892882 DOI: 10.1021/acs.jafc.8b05032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 12.5] [Reference Citation Analysis]
35 Corte CD, Iasevoli S, Strologo AD, Sanseviero M, Nobili V. Omega-3 Fatty Acids and Fatty Liver Disease in Children. Adv Food Nutr Res 2018;85:59-77. [PMID: 29860977 DOI: 10.1016/bs.afnr.2018.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Dikker O, Dağ H. The Connection between Celiac Disease and Hepatic Steatosis: High Levels of Pigment Epithelium-Derived Factor. Med Princ Pract 2020;29:201. [PMID: 31550729 DOI: 10.1159/000503633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
37 Seif El-Din SH, Salem MB, El-Lakkany NM, Hammam OA, Nasr SM, Okasha H, Ahmed LA, Saleh S, Botros SS. Early intervention with probiotics and metformin alleviates liver injury in NAFLD rats via targeting gut microbiota dysbiosis and p-AKT/mTOR/LC-3II pathways. Hum Exp Toxicol 2021;40:1496-509. [PMID: 33678036 DOI: 10.1177/0960327121999445] [Reference Citation Analysis]
38 Wang Y, Zhu Y, Niu J, Deng Q, Guo S, Jiang H, Peng Z, Xue Y, Peng H, Xuan L, Pan G. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters. Toxicol Appl Pharmacol 2020;404:115169. [PMID: 32738331 DOI: 10.1016/j.taap.2020.115169] [Reference Citation Analysis]
39 Wu Q, Liu J, Liu L, Chen Y, Wang J, Leng L, Yu Q, Duan Z, Wang Y. Establishment of an ex Vivo Model of Nonalcoholic Fatty Liver Disease Using a Tissue-Engineered Liver. ACS Biomater Sci Eng 2018;4:3016-26. [DOI: 10.1021/acsbiomaterials.8b00652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Teimouri M, Hosseini H, Shabani M, Koushki M, Noorbakhsh F, Meshkani R. Inhibiting miR-27a and miR-142-5p attenuate nonalcoholic fatty liver disease by regulating Nrf2 signaling pathway. IUBMB Life 2020;72:361-72. [PMID: 31889412 DOI: 10.1002/iub.2221] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
41 Asgari-Taee F, Zerafati-Shoae N, Dehghani M, Sadeghi M, Baradaran HR, Jazayeri S. Association of sugar sweetened beverages consumption with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Nutr 2019;58:1759-69. [PMID: 29761318 DOI: 10.1007/s00394-018-1711-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
42 Qiu Y, Wang S, Wan T, Ye M, Jiang R, Pei L, Yang L. Blood-based novel biomarkers for nonalcoholic steatohepatitis. Biomark Med 2018;12:501-15. [PMID: 29712439 DOI: 10.2217/bmm-2017-0361] [Reference Citation Analysis]
43 Braud L, Battault S, Meyer G, Nascimento A, Gaillard S, de Sousa G, Rahmani R, Riva C, Armand M, Maixent J, Reboul C. Antioxidant properties of tea blunt ROS-dependent lipogenesis: beneficial effect on hepatic steatosis in a high fat-high sucrose diet NAFLD obese rat model. The Journal of Nutritional Biochemistry 2017;40:95-104. [DOI: 10.1016/j.jnutbio.2016.10.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
44 Pritchard MT, McCracken JM. Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar? Curr Drug Targets 2015;16:1332-46. [PMID: 26302807 DOI: 10.2174/1389450116666150825111439] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
45 Casey GR, Stains CI. Interrogating Protein Phosphatases with Chemical Activity Probes. Chemistry 2018;24:7810-24. [PMID: 29338103 DOI: 10.1002/chem.201705194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
46 Abenavoli L, Boccuto L. Is possible to detect nonalcoholic fatty liver disease by a new index including single nucleotide polymorphisms (SNPs)? Ann Transl Med 2018;6:366. [PMID: 30370293 DOI: 10.21037/atm.2018.09.20] [Reference Citation Analysis]
47 Marino L, Jornayvaz FR. Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol 2015; 21(39): 11053-11076 [PMID: 26494962 DOI: 10.3748/wjg.v21.i39.11053] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
48 Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, Federico A, Persico M. Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev 2018;2018:9547613. [PMID: 29991976 DOI: 10.1155/2018/9547613] [Cited by in Crossref: 205] [Cited by in F6Publishing: 209] [Article Influence: 68.3] [Reference Citation Analysis]
49 Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. World J Hepatol 2017; 9(15): 697-703 [PMID: 28596817 DOI: 10.4254/wjh.v9.i15.697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
50 Sorrentino G, Crispino P, Coppola D, De Stefano G. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. Drugs R D. 2015;15:21-25. [PMID: 25732561 DOI: 10.1007/s40268-015-0084-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
51 Asadollahpoor A, Abdollahi M, Rahimi R. Pimpinella anisum L. fruit: Chemical composition and effect on rat model of nonalcoholic fatty liver disease. J Res Med Sci 2017;22:37. [PMID: 28465696 DOI: 10.4103/1735-1995.202147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
52 Huang Y, Lang H, Chen K, Zhang Y, Gao Y, Ran L, Yi L, Mi M, Zhang Q. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway. Appl Physiol Nutr Metab 2020;45:227-39. [PMID: 31173696 DOI: 10.1139/apnm-2019-0057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
53 Beck JR, Cabral F, Rasineni K, Casey CA, Harris EN, Stains CI. A Panel of Protein Kinase Chemosensors Distinguishes Different Types of Fatty Liver Disease. Biochemistry 2019;58:3911-7. [PMID: 31433166 DOI: 10.1021/acs.biochem.9b00547] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Hoang-Yen Tran D, Hoang-Ngoc Tran D, Mattai SA, Sallam T, Ortiz C, Lee EC, Robbins L, Ho S, Lee JE, Fisseha E, Shieh C, Sideri A, Shih DQ, Fleshner P, McGovern DP, Vu M, Hing TC, Bakirtzi K, Cheng M, Su B, Law I, Karagiannides I, Targan SR, Gallo RL, Li Z, Koon HW. Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor. Int J Obes (Lond) 2016;40:1424-34. [PMID: 27163748 DOI: 10.1038/ijo.2016.90] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
55 Chen XJ, Liu WJ, Wen ML, Liang H, Wu SM, Zhu YZ, Zhao JY, Dong XQ, Li MG, Bian L, Zou CG, Ma LQ. Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats. Sci Rep 2017;7:41144. [PMID: 28106137 DOI: 10.1038/srep41144] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
56 Qiu X, Gao DH, Xiang X, Xiong YF, Zhu TS, Liu LG, Sun XF, Hao LP. Ameliorative effects of lutein on non-alcoholic fatty liver disease in rats. World J Gastroenterol 2015; 21(26): 8061-8072 [PMID: 26185377 DOI: 10.3748/wjg.v21.i26.8061] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
57 Wahlang B, McClain C, Barve S, Gobejishvili L. Role of cAMP and phosphodiesterase signaling in liver health and disease. Cell Signal 2018;49:105-15. [PMID: 29902522 DOI: 10.1016/j.cellsig.2018.06.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
58 Marušić M, Paić M, Knobloch M, Liberati Pršo AM. NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2. Can J Gastroenterol Hepatol 2021;2021:6613827. [PMID: 33681089 DOI: 10.1155/2021/6613827] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Manne V, Handa P, Kowdley KV. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin Liver Dis 2018;22:23-37. [PMID: 29128059 DOI: 10.1016/j.cld.2017.08.007] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 20.3] [Reference Citation Analysis]
60 Mlynarsky L, Schlesinger D, Lotan R, Webb M, Halpern Z, Santo E, Shibolet O, Zelber-Sagi S. Non-alcoholic fatty liver disease is not associated with a lower health perception. World J Gastroenterol 2016; 22(17): 4362-4372 [PMID: 27158205 DOI: 10.3748/wjg.v22.i17.4362] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
61 Katsagoni CN, Papatheodoridis GV, Papageorgiou MV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Fragopoulou E, Kontogianni MD. A "healthy diet-optimal sleep" lifestyle pattern is inversely associated with liver stiffness and insulin resistance in patients with nonalcoholic fatty liver disease. Appl Physiol Nutr Metab 2017;42:250-6. [PMID: 28133993 DOI: 10.1139/apnm-2016-0492] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
62 Soto-Angona Ó, Anmella G, Valdés-Florido MJ, De Uribe-Viloria N, Carvalho AF, Penninx BWJH, Berk M. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC Med 2020;18:261. [PMID: 32998725 DOI: 10.1186/s12916-020-01713-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
63 Colica C, Boccuto L, Abenavoli L. Silymarin: An option to treat non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(47): 8437-8438 [PMID: 29309065 DOI: 10.3748/wjg.v23.i47.8437] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
64 Gallego-Durán R, Romero-Gómez M. Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. World J Hepatol 2015; 7(24): 2497-2502 [PMID: 26523202 DOI: 10.4254/wjh.v7.i24.2497] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
65 Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016;65:1109-23. [DOI: 10.1016/j.metabol.2016.05.003] [Cited by in Crossref: 177] [Cited by in F6Publishing: 160] [Article Influence: 35.4] [Reference Citation Analysis]
66 Yeh YT, Cho YY, Hsieh SC, Chiang AN. Chinese olive extract ameliorates hepatic lipid accumulation in vitro and in vivo by regulating lipid metabolism. Sci Rep 2018;8:1057. [PMID: 29348600 DOI: 10.1038/s41598-018-19553-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
67 Murillo AG, DiMarco DM, Fernandez ML. The Potential of Non-Provitamin A Carotenoids for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease. Biology (Basel). 2016;5. [PMID: 27834813 DOI: 10.3390/biology5040042] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
68 Marques E, Pfohl M, Auclair A, Jamwal R, Barlock BJ, Sammoura FM, Goedken M, Akhlaghi F, Slitt AL. Perfluorooctanesulfonic acid (PFOS) administration shifts the hepatic proteome and augments dietary outcomes related to hepatic steatosis in mice. Toxicol Appl Pharmacol 2020;408:115250. [PMID: 32979393 DOI: 10.1016/j.taap.2020.115250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
69 Cheraghpour M, Imani H, Ommi S, Alavian SM, Karimi-Shahrbabak E, Hedayati M, Yari Z, Hekmatdoost A. Hesperidin improves hepatic steatosis, hepatic enzymes, and metabolic and inflammatory parameters in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled, double-blind clinical trial. Phytother Res 2019;33:2118-25. [PMID: 31264313 DOI: 10.1002/ptr.6406] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
70 Sharma K, Zajc I, Žiberna L. Dietary vitamin D equilibrium in serum ameliorates direct bilirubin associated diabetes mellitus. Chem Biol Interact 2021;337:109399. [PMID: 33503443 DOI: 10.1016/j.cbi.2021.109399] [Reference Citation Analysis]
71 Rizzatti G, Matteo MV, Ianiro G, Cammarota G, Franceschi F, Gasbarrini A. Helicobacter pylori in metabolic related diseases. Minerva Gastroenterol Dietol 2018;64. [DOI: 10.23736/s1121-421x.18.02490-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
72 Crespo M, Lappe S, Feldstein AE, Alkhouri N. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease. Metabolism 2016;65:1161-71. [DOI: 10.1016/j.metabol.2016.01.008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 7.6] [Reference Citation Analysis]
73 Nelson JE, Handa P, Aouizerat B, Wilson L, Vemulakonda LA, Yeh MM, Kowdley KV; NASH Clinical Research Network. Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Aliment Pharmacol Ther 2016;44:1253-64. [PMID: 27730688 DOI: 10.1111/apt.13824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
74 Mello T, Materozzi M, Galli A. PPARs and Mitochondrial Metabolism: From NAFLD to HCC. PPAR Res 2016;2016:7403230. [PMID: 28115925 DOI: 10.1155/2016/7403230] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
75 Kaliora AC, Kalafati IP, Gioxari A, Diolintzi A, Kokkinos A, Dedoussis GV. A modified response of NAFLD patients with non-significant fibrosis in nutritional counseling according to GCKR rs1260326. Eur J Nutr 2018;57:2227-35. [PMID: 28695325 DOI: 10.1007/s00394-017-1499-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
76 Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol 2018;31:296-304. [PMID: 29720855 DOI: 10.20524/aog.2018.0248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
77 Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol 2017; 9(2): 91-98 [PMID: 28144390 DOI: 10.4254/wjh.v9.i2.91] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
78 Yan J, Yu Y, Kang JW, Tam ZY, Xu S, Fong ELS, Singh SP, Song Z, Tucker-Kellogg L, So PTC, Yu H. Development of a classification model for non-alcoholic steatohepatitis (NASH) using confocal Raman micro-spectroscopy. J Biophotonics 2017;10:1703-13. [PMID: 28635128 DOI: 10.1002/jbio.201600303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
79 Motiño O, Agra N, Brea Contreras R, Domínguez-moreno M, García-monzón C, Vargas-castrillón J, Carnovale CE, Boscá L, Casado M, Mayoral R, Valdecantos MP, Valverde ÁM, Francés DE, Martín-sanz P. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2016;1862:1710-23. [DOI: 10.1016/j.bbadis.2016.06.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
80 Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, Younossi ZM. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World J Gastroenterol 2016; 22(27): 6318-6327 [PMID: 27468220 DOI: 10.3748/wjg.v22.i27.6318] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 62] [Article Influence: 14.4] [Reference Citation Analysis]
81 Guo Y, Ding PH, Liu LJ, Shi L, Mao TY, Li JX, Wang YL. Gegen Qinlian Decoction Attenuates High-Fat Diet-Induced Steatohepatitis in Rats via Gut Microbiota. Evid Based Complement Alternat Med 2018;2018:7370891. [PMID: 30671129 DOI: 10.1155/2018/7370891] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
82 Makri E, Cholongitas E, Tziomalos K. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(41): 9039-9043 [PMID: 27895393 DOI: 10.3748/wjg.v22.i41.9039] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
83 Gan L, Xiang W, Xie B, Yu L. Molecular mechanisms of fatty liver in obesity. Front Med 2015;9:275-87. [PMID: 26290284 DOI: 10.1007/s11684-015-0410-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
84 Gu J, Yao M, Yao D, Wang L, Yang X, Yao D. Nonalcoholic Lipid Accumulation and Hepatocyte Malignant Transformation. J Clin Transl Hepatol. 2016;4:123-130. [PMID: 27350942 DOI: 10.14218/jcth.2016.00010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
85 Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E, Luzza F. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients 2017;9:E870. [PMID: 28805669 DOI: 10.3390/nu9080870] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
86 Izdebska M, Piątkowska-chmiel I, Korolczuk A, Herbet M, Gawrońska-grzywacz M, Gieroba R, Sysa M, Czajkowska-bania K, Cygal M, Korga A, Dudka J. The beneficial effects of resveratrol on steatosis and mitochondrial oxidative stress in HepG2 cells. Can J Physiol Pharmacol 2017;95:1442-53. [DOI: 10.1139/cjpp-2016-0561] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
87 Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9. [PMID: 32518675 DOI: 10.1186/s40842-020-00097-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
88 Chan R, Wong VW, Chu WC, Wong GL, Li LS, Leung J, Chim AM, Yeung DK, Sea MM, Woo J. Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. PLoS One. 2015;10:e0139310. [PMID: 26418083 DOI: 10.1371/journal.pone.0139310] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
89 Kosmalski M, Mokros Ł, Kuna P, Witusik A, Pietras T. Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease. Cent Eur J Immunol 2018;43:231-9. [PMID: 30135638 DOI: 10.5114/ceji.2018.77395] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
90 He C, Cheng D, Wang H, Wu K, Zhu Y, Lu N. Helicobacter pylori infection aggravates diet-induced nonalcoholic fatty liver in mice. Clinics and Research in Hepatology and Gastroenterology 2018;42:360-7. [DOI: 10.1016/j.clinre.2017.12.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
91 Abenavoli L, Milic N, Luzza F, Boccuto L, De Lorenzo A. Polyphenols Treatment in Patients with Nonalcoholic Fatty Liver Disease. J Transl Int Med. 2017;5:144-147. [PMID: 29164049 DOI: 10.1515/jtim-2017-0027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
92 Yoshitaka H, Hamaguchi M, Kojima T, Fukuda T, Ohbora A, Fukui M. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study. Medicine (Baltimore). 2017;96:e6712. [PMID: 28471965 DOI: 10.1097/md.0000000000006712] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 9.3] [Reference Citation Analysis]
93 Muriel P. The Liver. Liver Pathophysiology. Elsevier; 2017. pp. 3-22. [DOI: 10.1016/b978-0-12-804274-8.00001-1] [Cited by in Crossref: 10] [Article Influence: 2.5] [Reference Citation Analysis]
94 Almatrafi MM, Vergara-Jimenez M, Murillo AG, Norris GH, Blesso CN, Fernandez ML. Moringa Leaves Prevent Hepatic Lipid Accumulation and Inflammation in Guinea Pigs by Reducing the Expression of Genes Involved in Lipid Metabolism. Int J Mol Sci 2017;18:E1330. [PMID: 28640194 DOI: 10.3390/ijms18071330] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
95 Dallio M, Sangineto M, Romeo M, Villani R, Romano AD, Loguercio C, Serviddio G, Federico A. Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. Int J Mol Sci 2021;22:E436. [PMID: 33406763 DOI: 10.3390/ijms22010436] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
96 Katsagoni CN, Georgoulis M, Papatheodoridis GV, Fragopoulou E, Ioannidou P, Papageorgiou M, Alexopoulou A, Papadopoulos N, Deutsch M, Kontogianni MD. Associations Between Lifestyle Characteristics and the Presence of Nonalcoholic Fatty Liver Disease: A Case-Control Study. Metab Syndr Relat Disord 2017;15:72-9. [PMID: 27869531 DOI: 10.1089/met.2016.0105] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
97 Komura T, Ohta H, Seike T, Shimizu Y, Nakai R, Omura H, Kagaya T, Kasashima S, Kawashima A, Oba S, Harada K, Kaneko S, Unoura M. The Efficacy of Corticosteroid Therapy in a Patient with Non-alcoholic Steatohepatitis Overlapping Autoimmune Hepatitis. Intern Med 2018;57:807-12. [PMID: 29151501 DOI: 10.2169/internalmedicine.8887-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Nobili V, Alisi A, Musso G, Scorletti E, Calder PC, Byrne CD. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Crit Rev Clin Lab Sci. 2016;53:106-120. [PMID: 26463349 DOI: 10.3109/10408363.2015.1092106] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
99 Lu YW, Zhu YC, Zhang L, Li P, Yang J, Wen XD. Ilexgenin A enhances the effects of simvastatin on non-alcoholic fatty liver disease without changes in simvastatin pharmacokinetics. Chin J Nat Med 2018;16:436-45. [PMID: 30047465 DOI: 10.1016/S1875-5364(18)30077-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
100 Yip WCY, Sequeira IR, Plank LD, Poppitt SD. Prevalence of Pre-Diabetes across Ethnicities: A Review of Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) for Classification of Dysglycaemia. Nutrients 2017;9:E1273. [PMID: 29165385 DOI: 10.3390/nu9111273] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 13.5] [Reference Citation Analysis]
101 Li Z, Lin M, Liu C, Chen Z, Wang D, Shi X, Yang S, Li XJ. The rs4686434 variant in the fetuin B (FETUB) locus is associated with intrahepatic triglyceride content in obese Chinese adults. J Diabetes 2018;10:916-25. [PMID: 29671945 DOI: 10.1111/1753-0407.12774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
102 Chen CC, Chang ZY, Tsai FJ, Chen SY. Cannabinoid receptor type 1 antagonist inhibits progression of obesity-associated nonalcoholic steatohepatitis in a mouse model by remodulating immune system disturbances. Immun Inflamm Dis 2020;8:544-58. [PMID: 32798334 DOI: 10.1002/iid3.338] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Vahid F, Shivappa N, Hekmatdoost A, R Hebert J, Poustchi H, Shamsipour A, Eslamparast T, Meibodi M, Rahmani D. Association of Pro-inflammatory Dietary Intake and Non-Alcoholic Fatty Liver Disease: Findings from Iranian case-control study. Int J Vitam Nutr Res 2018;88:144-50. [PMID: 30887902 DOI: 10.1024/0300-9831/a000571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
104 Aliasghari F, Izadi A, Jabbari M, Imani B, Gargari BP, Asjodi F, Ebrahimi S. Are Vaspin and Omentin-1 Related to Insulin Resistance, Blood Pressure and Inflammation in NAFLD Patients? J Med Biochem 2018;37:470-5. [PMID: 30584407 DOI: 10.2478/jomb-2018-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
105 Barbosa RJ, Ratti da Silva G, Cola IM, Kuchler JC, Coelho N, Barboza LN, Menetrier JV, de Souza R, Zonta FN, Froehlich DL, Jacomassi E, Soares AA, Velasques LG, Veiga AA, Souza LM, Lovato ECW, Ribeiro-Paes JT, Gasparotto Junior A, Acco A, Lívero FADR. Promising therapeutic use of Baccharis trimera (less.) DC. as a natural hepatoprotective agent against hepatic lesions that are caused by multiple risk factors. J Ethnopharmacol 2020;254:112729. [PMID: 32145332 DOI: 10.1016/j.jep.2020.112729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol. 2016;30:282-287. [PMID: 26537011 DOI: 10.1111/jdv.13456] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
107 Mody A, White D, Kanwal F, Garcia JM. Relevance of low testosterone to non-alcoholic fatty liver disease. Cardiovasc Endocrinol 2015;4:83-9. [PMID: 26405614 DOI: 10.1097/XCE.0000000000000057] [Cited by in Crossref: 24] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
108 Abenavoli L, Izzo AA, Milić N, Cicala C, Santini A, Capasso R. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res 2018;32:2202-13. [PMID: 30080294 DOI: 10.1002/ptr.6171] [Cited by in Crossref: 121] [Cited by in F6Publishing: 97] [Article Influence: 40.3] [Reference Citation Analysis]
109 Abenavoli L, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol 2016; 22(31): 7006-7016 [PMID: 27610012 DOI: 10.3748/wjg.v22.i31.7006] [Cited by in CrossRef: 98] [Cited by in F6Publishing: 94] [Article Influence: 19.6] [Reference Citation Analysis]
110 Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Adiposity May Moderate the Link Between Choline Intake and Non-alcoholic Fatty Liver Disease. J Am Coll Nutr 2019;38:633-9. [PMID: 31305223 DOI: 10.1080/07315724.2018.1507011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
111 Abenavoli L, Di Renzo L, De Lorenzo A. Body Composition and Non-alcoholic Fatty Liver Disease. J Lifestyle Med 2016;6:47-8. [PMID: 27358840 DOI: 10.15280/jlm.2016.6.1.47] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
112 Kaliora AC, Kokkinos A, Diolintzi A, Stoupaki M, Gioxari A, Kanellos PT, Dedoussis GVZ, Vlachogiannakos J, Revenas C, Ladas SD, Karathanos VT. The effect of minimal dietary changes with raisins in NAFLD patients with non-significant fibrosis: a randomized controlled intervention. Food Funct 2016;7:4533-44. [DOI: 10.1039/c6fo01040g] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
113 Pfirrmann D, Huber Y, Schattenberg JM, Simon P. Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study. J Med Internet Res 2019;21:e11250. [PMID: 30602434 DOI: 10.2196/11250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
114 Mazidi M, Katsiki N, Banach M. A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study. J Nutr Biochem 2019;65:66-71. [PMID: 30623852 DOI: 10.1016/j.jnutbio.2018.10.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
115 Muramatsu-Kato K, Itoh H, Kohmura-Kobayashi Y, Ferdous UJ, Tamura N, Yaguchi C, Uchida T, Suzuki K, Hashimoto K, Suganami T, Ogawa Y, Kanayama N. Undernourishment in utero Primes Hepatic Steatosis in Adult Mice Offspring on an Obesogenic Diet; Involvement of Endoplasmic Reticulum Stress. Sci Rep 2015;5:16867. [PMID: 26581663 DOI: 10.1038/srep16867] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
116 Zamani N, Shams M, Nimrouzi M, Zarshenas MM, Abolhasani Foroughi A, Fallahzadeh Abarghooei E, Fattahi MR. The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo-controlled clinical trial. Complement Ther Med 2018;41:118-23. [PMID: 30477827 DOI: 10.1016/j.ctim.2018.09.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
117 Dajani A, AbuHammour A. Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. Saudi J Gastroenterol. 2016;22:91-105. [PMID: 26997214 DOI: 10.4103/1319-3767.178527] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
118 Salehi-Sahlabadi A, Teymoori F, Jabbari M, Momeni A, Mokari-Yamchi A, Sohouli M, Hekmatdoost A. Dietary polyphenols and the odds of non-alcoholic fatty liver disease: A case-control study. Clin Nutr ESPEN 2021;41:429-35. [PMID: 33487302 DOI: 10.1016/j.clnesp.2020.09.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Onat A, Can G, Kaya A, Akbaş T, Özpamuk-Karadeniz F, Şimşek B, Çakır H, Yüksel H. Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality. World J Gastroenterol 2015; 21(48): 13555-13565 [PMID: 26730168 DOI: 10.3748/wjg.v21.i48.13555] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
120 Mazidi M, Mikhailidis DP, Banach M. Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based study. Clin Nutr 2020;39:3730-5. [PMID: 32928581 DOI: 10.1016/j.clnu.2020.03.035] [Reference Citation Analysis]
121 Ilan Y. Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need? Dig Dis Sci 2018;63:1726-36. [DOI: 10.1007/s10620-018-5080-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
122 Abenavoli L, Larussa T, Corea A, Procopio AC, Boccuto L, Dallio M, Federico A, Luzza F. Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:494. [PMID: 33546130 DOI: 10.3390/nu13020494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
123 Povero D, Feldstein AE. Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis. Diabetes Metab J 2016;40:1-11. [PMID: 26912150 DOI: 10.4093/dmj.2016.40.1.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
124 Vonghia L, Francque S. Cross talk of the immune system in the adipose tissue and the liver in non-alcoholic steatohepatitis: Pathology and beyond. World J Hepatol 2015; 7(15): 1905-1912 [PMID: 26244065 DOI: 10.4254/wjh.v7.i15.1905] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
125 Abenavoli L, Di Renzo L, Boccuto L, Alwardat N, Gratteri S, De Lorenzo A. Health benefits of Mediterranean diet in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2018;12:873-881. [PMID: 30033779 DOI: 10.1080/17474124.2018.1503947] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
126 Nunez DJ, Alexander M, Yerges-Armstrong L, Singh G, Byttebier G, Fabbrini E, Waterworth D, Meininger G, Galwey N, Wallentin L, White HD, Vannieuwenhuyse B, Alazawi W, Kendrick S, Sattar N, Ferrannini E. Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. Am J Physiol Gastrointest Liver Physiol 2019;316:G372-86. [PMID: 30495974 DOI: 10.1152/ajpgi.00051.2018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
127 Martins E, Oliveira A. NAFLD and cardiovascular disease. Porto Biomed J 2018;3:e2. [PMID: 31595238 DOI: 10.1016/j.pbj.0000000000000002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
128 Lin H, Li Q, Liu X, Ma H, Xia M, Wang D, Li X, Wu J, Zhao N, Pan B, Gao X. Liver Fat Content Is Associated with Elevated Serum Uric Acid in the Chinese Middle-Aged and Elderly Populations: Shanghai Changfeng Study. PLoS One 2015;10:e0140379. [PMID: 26473493 DOI: 10.1371/journal.pone.0140379] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
129 Flisiak-Jackiewicz M, Bobrus-Chociej A, Tarasów E, Wojtkowska M, Białokoz-Kalinowska I, Lebensztejn DM. Predictive Role of Interleukin-18 in Liver Steatosis in Obese Children. Can J Gastroenterol Hepatol 2018;2018:3870454. [PMID: 29854715 DOI: 10.1155/2018/3870454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
130 Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Link between plasma trans-fatty acid and fatty liver is moderated by adiposity. Int J Cardiol 2018;272:316-22. [PMID: 30072152 DOI: 10.1016/j.ijcard.2018.07.061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
131 Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol 2020;19:134-44. [PMID: 31606352 DOI: 10.1016/j.aohep.2019.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
132 Zhai H, Chen C, Wang N, Chen Y, Nie X, Han B, Li Q, Xia F, Lu Y. Blood lead level is associated with non-alcoholic fatty liver disease in the Yangtze River Delta region of China in the context of rapid urbanization. Environ Health 2017;16:93. [PMID: 28859656 DOI: 10.1186/s12940-017-0304-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
133 Troisi J, Cavallo P, Colucci A, Pierri L, Scala G, Symes S, Jones C, Richards S. Metabolomics in genetic testing. Adv Clin Chem 2020;94:85-153. [PMID: 31952575 DOI: 10.1016/bs.acc.2019.07.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
134 Wang D, Liu Y, Liu S, Lin L, Liu C, Shi X, Chen Z, Lin M, Yang S, Li Z, Li X. Serum fetuin-B is positively associated with intrahepatic triglyceride content and increases the risk of insulin resistance in obese Chinese adults: A cross-sectional study: 在中国肥胖成年人中血清胎球蛋白B水平与肝内甘油三酯含量呈正相关并增加胰岛素抵抗风险:一项横断面研究. Journal of Diabetes 2018;10:581-8. [DOI: 10.1111/1753-0407.12632] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
135 Kim J, Ha T, Kim S, Lee S, Ahn J. Red paprika ( Capsicum annuum L.) and its main carotenoid capsanthin ameliorate impaired lipid metabolism in the liver and adipose tissue of high-fat diet-induced obese mice. Journal of Functional Foods 2017;31:131-40. [DOI: 10.1016/j.jff.2017.01.044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
136 Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments. Nutrients 2017;9:E387. [PMID: 28420094 DOI: 10.3390/nu9040387] [Cited by in Crossref: 166] [Cited by in F6Publishing: 139] [Article Influence: 41.5] [Reference Citation Analysis]
137 Rosato V, Masarone M, Dallio M, Federico A, Aglitti A, Persico M. NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome. Int J Environ Res Public Health 2019;16:E3415. [PMID: 31540048 DOI: 10.3390/ijerph16183415] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
138 Mazidi M, Katsiki N, Mikhailidis DP, Banach M. Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey. Atherosclerosis 2019;284:129-35. [PMID: 30878840 DOI: 10.1016/j.atherosclerosis.2018.11.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
139 Tryndyak VP, Marrone AK, Latendresse JR, Muskhelishvili L, Beland FA, Pogribny IP. MicroRNA changes, activation of progenitor cells and severity of liver injury in mice induced by choline and folate deficiency. The Journal of Nutritional Biochemistry 2016;28:83-90. [DOI: 10.1016/j.jnutbio.2015.10.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
140 Cheng DD, He C, Ai HH, Huang Y, Lu NH. The Possible Role of Helicobacter pylori Infection in Non-alcoholic Fatty Liver Disease. Front Microbiol 2017;8:743. [PMID: 28539915 DOI: 10.3389/fmicb.2017.00743] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
141 Munera-Campos M, Vilar-Alejo J, Rivera R, Carrascosa JM, Daudén E, Herrera-Acosta E, Sahuquillo-Torralba A, Gómez-García FJ, Baniandrés-Rodríguez O, de la Cueva P, López-Estebaranz JL, Belinchón I, Ferran M, Riera-Monroig J, Rodriguez L, Carretero G, García-Donoso C, Ballescá F, Llamas-Velasco M, Herrera-Ceballos E, Pujol-Marco C, Nieto-Benito LM, Ruiz-Genao DP, Alsina M, Descalzo MA, García-Doval I; BIOBADADERM Study Group. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. J Dermatolog Treat 2021;:1-28. [PMID: 33913796 DOI: 10.1080/09546634.2021.1922572] [Reference Citation Analysis]
142 Xing J, Guan X, Zhang Q, Chen S, Wu S, Sun X. Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Obes Facts 2021;14:190-6. [PMID: 33780962 DOI: 10.1159/000514848] [Reference Citation Analysis]
143 Stacchiotti A, Favero G, Lavazza A, Golic I, Aleksic M, Korac A, Rodella LF, Rezzani R. Hepatic Macrosteatosis Is Partially Converted to Microsteatosis by Melatonin Supplementation in ob/ob Mice Non-Alcoholic Fatty Liver Disease. PLoS One 2016;11:e0148115. [PMID: 26824477 DOI: 10.1371/journal.pone.0148115] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 6.8] [Reference Citation Analysis]
144 Fan N, Peng L, Xia Z, Zhang L, Song Z, Wang Y, Peng Y. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 2019;18:39. [PMID: 30711017 DOI: 10.1186/s12944-019-0986-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
145 Ashraf NU, Altaf M. Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease. Mutat Res Rev Mutat Res 2018;778:1-12. [PMID: 30454678 DOI: 10.1016/j.mrrev.2018.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
146 Gómez-Zorita S, González-Arceo M, Trepiana J, Aguirre L, Crujeiras AB, Irles E, Segues N, Bujanda L, Portillo MP. Comparative Effects of Pterostilbene and Its Parent Compound Resveratrol on Oxidative Stress and Inflammation in Steatohepatitis Induced by High-Fat High-Fructose Feeding. Antioxidants (Basel) 2020;9:E1042. [PMID: 33114299 DOI: 10.3390/antiox9111042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
147 Beck JR, Harris EN, Stains CI. Quantification of Cell Signaling Networks Using Kinase Activity Chemosensors. Methods Mol Biol 2017;1636:61-70. [PMID: 28730472 DOI: 10.1007/978-1-4939-7154-1_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
148 He B, Wu L, Xie W, Shao Y, Jiang J, Zhao Z, Yan M, Chen Z, Cui D. The imbalance of Th17/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice. BMC Immunol 2017;18:33. [PMID: 28646856 DOI: 10.1186/s12865-017-0215-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 8.3] [Reference Citation Analysis]
149 Cui H, Li Y, Cao M, Liao J, Liu X, Miao J, Fu H, Song R, Wen W, Zhang Z, Wang H. Untargeted Metabolomic Analysis of the Effects and Mechanism of Nuciferine Treatment on Rats With Nonalcoholic Fatty Liver Disease. Front Pharmacol 2020;11:858. [PMID: 32581811 DOI: 10.3389/fphar.2020.00858] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
150 Salter DM, Wei W, Nahar PP, Marques E, Slitt AL. Perfluorooctanesulfonic Acid (PFOS) Thwarts the Beneficial Effects of Calorie Restriction and Metformin. Toxicol Sci 2021;182:82-95. [PMID: 33844015 DOI: 10.1093/toxsci/kfab043] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Dallio M, Masarone M, Errico S, Gravina AG, Nicolucci C, Di Sarno R, Gionti L, Tuccillo C, Persico M, Stiuso P, Diano N, Loguercio C, Federico A. Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. Aliment Pharmacol Ther 2018;47:826-37. [DOI: 10.1111/apt.14499] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
152 Wang ST, Zheng J, Peng HW, Cai XL, Pan XT, Li HQ, Hong QZ, Peng XE. Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. BMC Gastroenterol 2020;20:66. [PMID: 32164541 DOI: 10.1186/s12876-020-01204-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
153 Abenavoli L, Boccuto L. Nonalcoholic fatty liver disease in obese adolescents: the role of genetic polymorphisms. Hepatobiliary Surg Nutr 2019;8:179-80. [PMID: 31098374 DOI: 10.21037/hbsn.2018.12.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]